Osmetech (fka osmef)

[grooverider]

Genmark and Osmetech

According to recent PR, Osmetech PLC Pink sheets stock will merge into Genmark which will be traded on the NASDAQ.

Conversion will be 1 Genmark Share for every 230 Osmetech Share

Initial price range is expected to be $8-10

[grooverider]

Osmetech Scheme of Arrangement, Breaking News

TIDMOMH

RNS Number : 0154M

Osmetech PLC

17 May 2010

?

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR

FROM THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE

A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT IS MADE IN ACCORDANCE WITH THE REQUIREMENTS OF THE AIM RULES

FOR COMPANIES.

Osmetech plc

Update regarding Scheme timetable, listing of GenMark on NASDAQ

and GenMark

Fundraising

Following the approval of the Scheme and associated matters at the Osmetech

Shareholder Meetings, the Board of Osmetech today provides the following update

in relation to the Scheme timetable, listing of GenMark on NASDAQ and the

GenMark Fundraising.

On 13 May 2010, GenMark filed Amendment Number 2 ("Amendment") to its

Registration Statement on Form S-1 originally filed with the United States

Securities and Exchange Commission on March 19, 2010 (file no. 333-165562). The

Amendment includes an initial estimate of the price range (US $8.00 to US

$10.00) at which the GenMark Shares are proposed to be issued in the GenMark

Fundraising. This price range is subject to further amendment and the GenMark

Directors are permitted to issue the GenMark Fundraising Shares outside any

published price range.

As set out in the Scheme Document, if fully implemented, the Scheme will result

in all Osmetech Shareholders becoming shareholders in GenMark, on the basis of

one GenMark Share for every 230 Osmetech Shares held at the Scheme Record Time.

Using a US$/UK sterling exchange rate of 0.6843, being the exchange rate

prevailing on 13 May 2010, the initial estimated price range equates to an

estimated value of between 2.38 pence and 2.98 pence for each Osmetech Share in

issue as at today's date.

A copy of the Amendment may be viewed on the Securities and Exchange Commission

website at www.sec.gov.

In view of the delay in the filing of the Amendment, the Court Hearing to

sanction to the Scheme has been rescheduled to take place on 26 May 2010, which

would delay the Effective Date of the Scheme to 1 June 2010 and the cancellation

of trading on AIM to 2 June 2010. The revised expected timetable is set out in

the appendix to this announcement, although it is emphasised that the dates

given are indicative only, and are subject to change.

Terms defined in the Scheme Circular shall have the same meaning(s) when used in

this announcement.

Contacts

For further information contact:

Osmetech plc

Steven Kemper, Chief Financial Officer - [phone]

Jon Faiz Kayyem, Chief Executive Officer - [phone]

Canaccord Genuity Limited

(Nominated Advisor)

020 7050 6500

Robert Finlay

Henry Fitzgerald-O'Connor

As of 10 May 2010, Canaccord Adams Limited, the Company's nominated adviser and

broker has changed its name to Canaccord Genuity Limited.

THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY

ANY SECURITIES OF GENMARK OR OSMETECH, NOR SHALL IT FORM THE BASIS OF, OR BE

RELIED UPON IN CONNECTION WITH ANY CONTRACT FOR SUCH PURCHASE OR SUBSCRIPTION.

THE GENMARK SHARES TO BE ISSUED PURSUANT TO THE SCHEME WILL ONLY BE ISSUED TO

OSMETECH SHAREHOLDERS IN ACCORDANCE WITH THE SCHEME AND THE SCHEME CIRCULAR.

the GenMark Shares to be issued pursuant to the Scheme will not be registered

with the SEC under the Securities Act, but will be issued in reliance upon an

exemption from the registration requirements.

A REGISTRATION STATEMENT RELATING TO THE ISSUANCE OF GENMARK SHARES IN THE

GENMARK FUNDRAISING HAS BEEN FILED WITH THE SEC BUT HAS NOT YET BECOME EFFECTIVE

AND IS SUBJECT TO AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO

BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE.

OFFERS OF THESE SECURITIES MAY BE MADE ONLY BY MEANS OF A PROSPECTUS MEETING THE

APPLICABLE REQUIREMENTS OF UNITED STATES LAWS AND REGULATIONS AND THE LAWS AND

REGULATIONS OF ANY OTHER JURISDICTION IN WHICH SUCH SECURITIES MAY BE LAWFULLY

OFFERED FOR SALE.

Apart from the responsibilities and liabilities, if any, which may be imposed on

Canaccord Adams by the FSMA or the regulatory regime established thereunder,

Canaccord Adams does not accept any responsibility whatsoever for the contents

of this announcement or for any statement made or purported to be made by it, or

on its behalf, in connection with Osmetech, GenMark, the Osmetech Shares, the

GenMark Shares or the Proposal. Canaccord Adams accordingly disclaims all and

any liability whether arising in tort, contract or otherwise (save as referred

to above) which it might otherwise have in respect of this statement or any such

statement.

Canaccord Adams, which is authorised and regulated in the United Kingdom by the

FSA, is acting exclusively for Osmetech and GenMark and no one else in

connection with the Proposal and will not be responsible to anyone other than

Osmetech and GenMark for providing the protections afforded to clients of

Canaccord Adams nor for providing advice in relation to the Proposal or the

contents of this announcement, or any matter referred to herein.

Statements in this announcement regarding the Scheme, including expectations

with respect to the Scheme and the timetable for completing the Scheme, the

ability to list the GenMark Shares on the NASDAQ Global Market and complete the

GenMark Fundraising, future financial operating results, potential benefits of

the Scheme, and future opportunities for Osmetech or GenMark as well as any

other statements about the future expectations, beliefs, goals, plans or

prospects of the management of Osmetech or GenMark constitute "forward-looking"

statements. Any statements that are not statements of historical fact

(including statements containing the words "believe", "plan", "anticipate",

"expect", "estimate", and similar expressions) should also be considered to be

forward-looking in nature. There are a number of important factors that could

cause actual results or events to differ materially from those indicated by such

forward-looking statements, including not obtaining the necessary approvals to

complete the Scheme on a timely basis, or at all, inability to complete the

GenMark Fundraising on favourable terms, or at all, decreases in demand for

Osmetech's products and other factors described in Osmetech's Annual Report for

the year ended 31 December 2008. Osmetech disclaims any intention or obligation

to update any forward-looking statements as a result of developments occurring

after the date of this announcement. Osmetech Shareholders are cautioned not to

place undue weight on these forward-looking statements. Actual results may

differ materially from those anticipated in such forward-looking statements even

if experience or future changes make it clear that any projected results

expressed or implied therein may not be realised.

APPENDIX

Expected timetable of principal events

The following indicative timetable sets out the expected dates for the

implementation of the Proposal.

+--------------------------------------------------------------------------------+--------------------------+

| Event | Time and/or date |

+--------------------------------------------------------------------------------+--------------------------+

| Reduction Record | 6.00 p.m. on 25 May |

| Time................................................. | 2010(1) |

+--------------------------------------------------------------------------------+--------------------------+

| Last day of dealings in Osmetech | Up until 4.30 p.m. on 25 |

| Shares..................... | May 2010(1) |

+--------------------------------------------------------------------------------+--------------------------+

| Suspension of trading of Osmetech | 7.00 a.m. on 26 May |

| Shares on AIM...... | 2010(1) |

+--------------------------------------------------------------------------------+--------------------------+

| Court Hearing to sanction the Scheme | 26 May 2010(1) |

| and Capital | |

| Reduction..................................................................... | |

+--------------------------------------------------------------------------------+--------------------------+

| Conditional dealings commence in | 2.00 p.m. (9.00 a.m. New |

| GenMark Fundraising | York time) on 26 May |

| Shares....................................................... | 2010(1) |

+--------------------------------------------------------------------------------+--------------------------+

| Last day and time for receipt of | 12.00 p.m. on 28 May |

| transfers of Osmetech Shares for | 2010(1) |

| registration................................................. | |

+--------------------------------------------------------------------------------+--------------------------+

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/nae/al?rnd=6j2gDbwTafmyOYHmCUKfMw%3D%3D. You can use this link on the day this article is published and the following day.



(MORE TO FOLLOW) Dow Jones Newswires

05-17-10 0247ET

Copyright (c) 2010 Dow Jones & Company, Inc.

[grooverider]

I plan on trying to get a hold of investors relations to see what is the direction of OSMEF in the bigger picture if they can tell me anything

[grooverider]

Also:

http://www.genomeweb.com/dxpgx/osmetechs-2009-revenues-rise-81-percent

This company is a profit generator!

[grooverider]

I would put this stock on a watch list, the entry point is cheap right now, and this company has a lot to offer if they succeed in raising the money for a US IPO.

[grooverider]

Who is Osmetech?

Osmetech plc is an AIM-listed public company on the London Stock Exchange under ticker symbol OMH. Osmetech plc is incorporated in England and Wales and its main country of operations is the US.


Osmetech plc was founded in 1993, developing electronic odour sensor (“e-nose”) technology. IPO followed in 1994 and in 1999, the Company changed its name from Aromascan to Osmetech refocusing the business on the opportunities within the global healthcare market. With the acquisition of the OPTI (blood gas) product line from Roche Diagnostics in 2003, the Critical Care Diagnostic Division was formed, which more than doubled its level of sales revenues in 3 years through a strong network of international distributors.

The Osmetech Molecular Diagnostics division was created from acquisitions of Molecular Sensing plc in October 2004 and Clinical Micro Sensors, Inc. from Motorola in July 2005. Recently, Osmetech divested its Critical Care Diagnostic Division and is now focused on accelerating the expansion and development of the Molecular Diagnostic Division.

Osmetech Molecular Diagnostics


Transforming molecular diagnostics into practical, cost-effective testing solutions.


As the demand for and acceptance of molecular diagnostic tests multiplies, so does the rate of testing decentralization. The movement of molecular diagnostic testing into the clinical laboratories of mid-size hospitals requires greater simplicity, flexible testing capabilities, and cost-effectiveness.

Osmetech Molecular Diagnostics is focused on providing cutting-edge, cost-effective molecular diagnostic technologies and tools that enable a broader range of hospitals and laboratories to offer molecular diagnostic services for improved patient care.

www.osmetech.com

[grooverider]

Osmetech Shareholders approve US IPO:

http://www.genomeweb.com/dxpgx/osmetech-shareholders-approve-us-ipo

[ditchpig]

This from "respected" UK invesment magazine Investors Chronicle.

4 November 2005
Sniffing out value

Once upon a time, Osmetech was best known for developing sensing technology that emulates the human nose. This is still a substantial part of its business, and the origin of its name (osme is Greek for smell). But a series of well-executed acquisitions over the past couple of years have turned it into a broader based diagnostics company. Today’s trading update, which has sent the shares 20 per cent higher, shows some of the rewards of those deals.

Osmetech bought the OPTI range of blood gas analysers from Roche, the Swiss healthcare giant, for just $2.5m at the start of 2003. The devices are used in operating theatres and emergency rooms to give quick read-outs of critical gas and electrolyte levels in patients’ bloodstreams. Although formerly owned by a Swiss company, OPTI had a US-based sales force.

And look what they’ve done: sales in the first six months were £3.74m, up 52 per cent on last year and considerably more than the price paid for the business. The growth came from a new version of an existing product, and strong sales of a related product used in the veterinary market.

The company says it’s not over yet, either: two new OPTI products are due to be launched shortly and management is talking about ‘a very strong end to the year.’ Market expectations for OPTI sales are likely to be ‘significantly exceeded’ in 2005 and 2006.

Osmetech has another division, Molecular Diagnostics, where acquisitions have also played a part. It bought Clinical Micro Sensors (CMS) from Motorola for around £3.7m, a deal which gave it access to more complex genetic diagnostic technology. The first products from this division are due on market in the first half of 2006.

It’s noticeable that both Roche and Motorola were happy to be paid partly in Osmetech shares. Roche ended up with $1m worth of them, and Motorola invested £3.7m and has warrants over more. The shares were issued at a penny each to Roche and 1.75p apiece to Motorola. The company has since had a 10-into-1 share consolidation, so at 17.5p (latest share price here) the shares are effectively unchanged since the CMS deal. House broker Evolution Securities was forecasting 2006 sales of £8.63m, giving a loss of £7.74m (check forecasts here) but those numbers are now likely to be upgraded. The shares look good value

[ditchpig]

Quite of a lot has been happening in the last few months its a bit of a job keeping on top of it all. To get an idea where we are at now here is a long in depth interview with James White by Ian Roberts, analyst for Wallstreet Reporter....VERY positive, upbeat and bullish...!!! Well worth listening to, and should surely bring more US interest!!

http://www.wallstreetreporter.com/profiles/Osmetechplc.html

614

[ditchpig]

Osmetech for the future.

I think most of us have been stiched up by EVO and the MM's games over the last couple of years, the real enemy is not each other it is EVO and the MM's. They are the fools we need to be making money off rather than giving it to them. This share needs people with balls of steel, you have to ride out the rough with the smooth, the ups and down and the pumps and dumps.
Study the company, look long and hard at what they are doing and how they are doing it. Look at the way Osmetech has transformed itself in the last 18 months. Look at the fundementals, look at the potential market for their products look at what the management have done to safe guard the long term future of the company.
Buying OPTI and MOLS were a strokes of genius and the company is still looking for similar deals. Despite all the knockers both on here and III Jimmy boy and co have done a great job stream lining the company and getting it focussed.
VIP5 and GENEDRIVE are going to be the real cash cows are a within 12 months of being launched. Osmetech will then have dipped two toes into a two multi billion dollar markets. By listening to the derampers and the notsoHOT pump and dump merchants now you could be kicking yourself in 18 months time.

Buy your shares and hold the bloody things. Don't sell them back to EVO at the first sign of a tree shake. EVO are well aware of what the future holds, why would they have backed Osmo financially if they did not? EVO will be hanging in to the glory days and so should you.
Become a TRUE INVESTOR Buy your thousand quids worth of shares and hold on to them through thick and thin.
18 Months from now I am sure you will be more than amply rewarded.
Have you got balls of steel or testicals of tissue?

[ditchpig]

<font color=RED> <font size=3>Welcome to Osmetech - LSE:OMH OTC:OSMEF


Hello all.
Hope you find something of interest in this thread.
The company has made some huge leaps forward in the last 18 months and the next 12 will see the company bring some world leading products to market.

VIP5 a device to test for multiple sexual diseases in a point of care setting. market size for such a product is estimated at being $20 billion.

Genedrive is a product which gives the company a strong entry point into the fastest growing market segment of DNA based diagnostics. Molecular diagnostics is the fastest growing market segment within the $20bn+ global diagnostics market, with annual growth of 20%+ expected to continue for the foreseeable future.

The company has recently recruited two highly regarded molecular diagnostics specialist to commercialise this technology.
http://www.osmetech.com/news/2004/pr131204_mgmt_mole_diag.htm

The group is well funded having around $6,000,000 in the bank at the last results and a well established product, OPTI, earning more than $6,000,000 a year. The company has recently launched an arterial blood sampler which is expected to generate revenues in excess of $2,000,000 a year but more importantly has just launched a new vetinary product, Vetstat, for Idexx.

Results are out on the 27 January and if you are looking for a short term punt a good run is expected over the next 4 trading days. Long term they look a very safe bet.

Have fun and good luck.
DP